GNI Group (TYO:2160) said its core subsidiary, Gyre Therapeutics, completed a public offering of common stock, raising about $23 million in gross proceeds, according to a Monday filing on the Tokyo Stock Exchange.
The offering closed on May 29, with Gyre issuing 2,555,555 shares at $9 apiece, including 333,333 shares from the underwriters' overallotment option, the filing said.
GNI said its ownership in Gyre has decreased to 80.69% from 83.03%, though the unit remains a consolidated subsidiary of the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。